The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines - Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch. - BioPharm

ADVERTISEMENT

The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines
Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch.


BioPharm International


4. Guébre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of skin dendritic cells. J. Virol. 2003;77(9):5218–5225.

5. Glenn, GM, Frech, SA, Kenney, RT, Ellingsworth, LR. Transcutaneous immunization: antigen and adjuvant delivery to the skin. In: Bronaugh RL, Maibach HI, editors. Percutaneous absorption: drugs, cosmetics, mechanisms, methods, 4th ed. New York: Informa Healthcare; 2005.

6. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol. 2006;304:247–268.

7. Glenn GM, Kenney RT. Transcutaneous immunization. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good M, editors. New generation vaccines, 3rd ed. New York: Marcel Dekker, Inc.; 2003.

8. Belyakov IM, Hammond SA, Ahlers JD, Glenn JA, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 2004;113:998–1007.

9. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij, JP. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2003;2:253–267.

10. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol. Allergy Clin. North Am. 2003;23:787–813.

11. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T-cell responses and boosting of existing immunity. Vaccine 2001;19:2701–2707.

12. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nature Med. 2000;6:1403–1406.

13. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 1999;67:1100–1106.

14. Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun. 2007;75:2163–2170.

15. Frech SA, Kenney RT, Spyr CA, Lazar H, Viret JF, Herzog C, Glück R, Glenn GM. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005;23(7):946–50.

16. Sack DA, Sack RB. Test for enterotoxigenic Escherichia coli using Y1 adrenal cells in miniculture. Infect. Immun. 1975;11:334–336.

17. US Food and Drug Administration. Guidance for industry. Stability testing of drug substances and drug products. Rockville, MD; June 1998.

18. Lucas TI, Bishara RH, Seevers RH. A stability program for the distribution of drug products. Pharm. Technol. 2004:68–73.

19. International Conference on Harmonization. Q1D, Bracketing and matrixing designs for stability testing of new drug substances and products. Geneva, Switzerland; Feb. 2002.

20. International Conference on Harmonization Code Q1A(R2). Stability testing of new drug substances and products. Geneva, Switzerland; Feb.2003.

21. Water activity. In: Official methods of analysis of the AOAC. 13th ed. AOAC International 32.004–32.009; 1980.

22. Troller JA, Bernard DT, Scott VN. Measurement of water activity. In: Speck ML, editor. The compendium of methods for the microbiological examination of food. Washington, D.C.: American Public Health Association, 1984. p. 124–134


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here